Novavax Inc (NVAX): Gary C Evans , director of Novavax Inc sold 18,998 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $6.50 per share for a total value of $123,487.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 25, 2016, Gary C Evans (director) sold 50,000 shares at $5.41 per share price.On Feb 1, 2016, John Trizzino (SVP, Commercial Operations) purchased 5,855 shares at $3.63 per share price.Also, On Feb 1, 2016, John A Iii Herrmann (SVP, General Counsel) purchased 2,072 shares at $4.38 per share price.On Feb 1, 2016, Gregory M Glenn (SVP, Research and Development) purchased 2,369 shares at $4.38 per share price.
Shares of Novavax (NVAX) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.18 points or -2.86% at $6.12 with 73,20,255 shares getting traded. Post opening the session at $6.31, the shares hit an intraday low of $6.01 and an intraday high of $6.3325 and the price vacillated in this range throughout the day. The company has a market cap of $1,657 M and the number of outstanding shares has been calculated to be 27,07,82,920 shares. The 52-week high of Novavax is $15.01 and the 52-week low is $4.075.
Company has been under the radar of several Street Analysts.Novavax is Initiated by Chardan Capital Markets to Neutral and the brokerage firm has set the Price Target at $5.75. The Rating was issued on Apr 4, 2016.
Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).